Terapie w programie lekowym:
Leki w katalogu chemioterapii:
Aflibercept
Bevacizumab
Capecitabine
Capecitabine (2)
Carboplatin
Cetuximab
Cisplatinum
Cyklophosphamidum
Dacarbazinum
Denosumab
Doxorubicinum
Etoposidum
Fluorouracilum
Ifosfamidum
Imatinibum
Irinotecanum
Lanreotidum
Octreotidum
Oxaliplatinum
Paclitaxel
Panitumumab
Regorafenib
Sorafenib
Sunitinib
Temozolomidum
Vincristinum
Vinorelbinum
Badania kliniczne w Polsce - zobacz więcej w 🔍 wyszukiwarce
- colorectal cancer
- rectal cancer
- » Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
- » Surgery Versus Endoscopic Resection for Incompletely Removed Early Colon CAnceR (SCAR)- a Randomized Controlled Trial
- » A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
- » An Open-label, Multicentre, Dose-escalation, First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours (colorectal Cancer, Ovarian Cancer, Pancreatic Cancer or Renal Cell Carcinoma)
- » A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy